Angiogenesis inhibitors and the need for anti-angiogenic therapeutics

Full text for this resource is not available from the Research Repository.

Dass, Crispin R, Tran, T. M. N and Choong, Peter F. M (2007) Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. Journal of Dental Research, 86 (10). pp. 927-936. ISSN 0022-0345


Angiogenesis is the formation of new blood vessels from pre-existing vessels to form capillary networks, which, among other diseases, such as diabetic retinopathy and macular degeneration, is particularly important for tumor growth and metastasis. Thus, depriving a tumor of its vascular supply by means of anti-angiogenic agents has been of great interest since its proposal in the 1970s. This review looks at the common angiogenic inhibitors (angiostatin, endostatin, maspin, pigment epithelium-derived factor, bevacizumab and other monoclonal antibodies, and zoledronic acid) and their current status in clinical trials.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.1177/154405910708601005
Official URL
Subjects Historical > FOR Classification > 1102 Cardiorespiratory Medicine and Haematology
Historical > Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
Keywords ResPubID18883, angiogenesis, therapy, blood vessel, cancer, vasculature
Citations in Scopus 34 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login